P217: Body composition changes during 12-month vosoritide treatment in children with hypochondroplasia: A DXA-based prospective study

Genetics in Medicine Open 2026 Open access

Read full text
Authors: Ruta Navardauskaite, Anqing Zhang, Roopa Kanakatti Shankar, Niusha Shafaei, Raheem Seaforth, Kimberly Pitner, Andrew Dauber, Nadia Merchant
DOI: 10.1016/j.gimo.2026.103711
Cited by: 0

Abstract

Hypochondroplasia (HCH) is a fibroblast growth factor receptor 3 (FGFR3)-related skeletal dysplasia characterized by disproportionate short stature and altered body proportions. Beyond growth impairment, individuals with HCH frequently display abnormal body composition and increased adiposity, which may contribute to adverse cardiometabolic outcomes. Vosoritide, a C-type natriuretic peptide (CNP) analog that promotes endochondral bone growth by antagonizing FGFR3 signaling, is approved for achondroplasia and has recently shown efficacy in improving growth velocity in children with HCH.

Fields of Study & Subjects

Connective tissue disorders research Growth Hormone and Insulin-like Growth Factors Bone Tumor Diagnosis and Treatments

Publication details

Journal / source
Genetics in Medicine Open
Volume
4
Pages
103711–103711
Publication date
1 January 2026
Language
EN